Triumpharma Inc. is a pioneer in developing systems and solutions for advanced drug delivery. We strive to bridge the gap between life science and modern healthcare.

Triumpharma Inc. develops technologies that enhance the performance of many of today's commonly available pharmaceutical products and new chemical entities that give raise to challenging bioavailability problems.

Triumpharma has strong technical capabilities to take products from feasibility to pilot scale. Triumpharma conducts formulation optimization studies, pre-clinical trials on animals, human clinical studies including bioavailability/ bioequivalence trial complying with the international guidelines. The company's core advantages are its extremely low-cost base, experienced staff with multi national experience, holding PhDs from western universities, high-quality research, a large pool of patient’s and volunteers, and fast formulation development meeting the necessary regulatory requirements.

Triumpharma’s goal is to achieve a leadership position in the bioanalytical sector through its commitment to serve excellence and technical expertise. All regulatory testing are conducted in accordance with GLP standards and internal SOPs.

The bio-analytical lab offer:

  • Method Development for small to complex molecules in various biological matrices.
  • Method transfer, cross-validations, full GLP validations
  • Method Validation of developed methods according to compliance standards dictated by FDA, EMA directives. Assessment of linearity, accuracy, specificity, matrix effects, diverse stability evaluations and assay ruggedness according to the validation plan.
  • Routine analysis of samples in biological samples according to latest international guidelines, and covered by in house standard operation procedures.
  • Incurred sample analysis.

This publication has been produced with the assistance of the European Union in cooperation with Jordan Enterprise Development Corporation. *

* The contents of this publication are the sole responsibility of Triumpharma and can in no way betaken to reflect the views of the European Union & Jordan Enterprise Development Corporation